Navigation Links
Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
Date:11/8/2013

(ARM™), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding.  In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America.  The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Imprimis' results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to enter into licensing arrangements with pharmacies, physicians and healthcare organizations or to otherwise commercialize its formulations, its ability to obtain intellectual property protection for its assets, the success of additional research and development activities related to its formulations, its ability to accurately estimate its expenses and cash burn, its ability to raise additional funds, its ability to acquire, develop, commercialize or market new formulations and to enter into strategic alliances and transactions,  the projected size of the potential market for our product candidates, unexpected new data, safety and technical issues, regulatory and market developments impacting compo
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
3. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
4. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
5. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
6. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
7. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
8. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
9. Imprimis Announces Key Leadership Appointments
10. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... the world,s largest medical device manufacturers, has agreed to ... (DOJ), the Office of the Inspector General for the ... in a qui tam suit related to cardiac rhythm ... pacemakers and implantable cardioverter defibrillators (ICDs). The ...
... the inventor of finger pulse oximetry and a leader ... Personal Finger Pulse Oximeter will be featured on "The ... at 7 a.m. EST and PST; 6 a.m. CST. ... Leonard, Nonin Medical Consumer Products Marketing Manager, is the ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Nonin Medical GO2™ Finger Pulse Oximeter to be Featured on "The Balancing Act" TV Show on Lifetime Television 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce ... ever created for kids with cancer. The Chemo Duck App, available ... filled with enjoyable games to help children of all ages living ... helps to keep kids entertained, educated and at ease while waiting ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... skills of tracking down objects by practicing detection of different ... it is claimed that by continuous practice a person can ... the individual to track and locate objects faster and more ... possessing two nostrils. , The Amazing Trial ,A ...
... must stop tippling if they want to recover from ... that researched the brain's capacity to regenerate.// ... provides evidence that excessive drinking for a long period ... portal EurekAlert. ,During abstinence, an alcoholic's brain ...
... to prepare for, the winter season can be busy ... stresses of holiday events can increase anxiety and cause ... common illnesses for adults, seasonal blues can be experienced ... said Waguih William IsHak, MD, medical director of the ...
... some brands of frozen ready meals including 20 Asda own ... fears that they may contain small pieces of glass. Customers ... ,The products came from Rye Valley Foods ... are one of the country's biggest food processors. The company ...
... anti-AIDS group from Los Angeles has pressed upon Viagra manufacturers ... essentially// pushes the drug’s use as a recreational drug. ... avidly by gay and bisexual men who are also patronizing ... with risks. The AIDS Healthcare Foundation is especially worried that ...
... being administered DPT (diphtheria, pertussis and tetanus) injection Saturday. About ... ,According to official sources, the deaths took place in ... from here. Twelve children have been admitted to Ara Sadar ... was launched for children below one year of age. ...
Cached Medicine News:Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 3
... AliMed® Turnbuckle Ankle Orthosis enables ... torque at the ankle joint to ... The splint features a pair of ... and eversion/inversion simultaneously. Simply adjust the ...
... the foot and ankle. The internal hind ... plantar flexion (2" high, this may vary ... plantar flexion in 1/8" increments by simply ... the wedge. Ideal for post-surgical or partial ...
Compression Ankle Support Four-way ankle compression support with reinforced triangular closed-heel design for comfort, mobility and longer wear. Reduces swelling and does not retain heat or moisture...
... Ankle Cryo/Cuff combines the therapeutic benefits of ... and cold to minimize pain. The cuff ... ankle providing maximum cryotherapy. The Ankle Cryo/Cuff ... available in a pediatric size.,All Cryo/Cuffs can ...
Medicine Products: